Results 81 to 90 of about 10,275 (197)

LRP6 Is a Functional Receptor for Attenuated Canine Distemper Virus. [PDF]

, 2023
Wild-type canine distemper virus (CDV) is an important pathogen of dogs as well as wildlife that can infect immune and epithelial cells through two known receptors: the signaling lymphocytic activation molecule (SLAM) and nectin-4, respectively ...
Dettwiler, Martina, Doench, John, Gradauskaite, Vaiva, Inglebert, Marine, Plattet, Philippe, Rottenberg, Sven, Scherer, Melanie, Shrestha, Neeta, Wyss, Marianne   +8 more
core   +1 more source

Nanobody–chlorin e6 conjugate for Nectin‐4‐mediated tumor targeting and enhanced photodynamic therapy

VIEW, EarlyView.
Nectin‐4 is frequently overexpressed in solid tumors, yet many PDT photosensitizers show poor water solubility and nonspecific uptake. A Nectin‐4‐targeted nanobody–chlorin e6 conjugate (NPC) improves aqueous solubility and selectively accumulates in Nectin‐4‐positive tumor cells.
Haodian Wan, Tao Ye, Yawei Bi, Jiayu Zhang, Wei Wu, Aochi Liu, Li Sun, Jie Lin, Ningli Chai, Manjie Zhang, Jian Ma   +10 more
wiley   +1 more source

Phocine distemper Virus: Current knowledge and future directions [PDF]

, 2014
Phocine distemper virus (PDV) was first recognized in 1988 following a massive epidemic in harbor and grey seals in north-western Europe. Since then, the epidemiology of infection in North Atlantic and Arctic pinnipeds has been investigated.
Baker, J.D. (Jason), Barbieri, M. (Michelle), Colegrove, K.M. (Kathleen M), De Guise, S. (Sylvain), di Guardo, G. (Giovanni), Dobson, A.P. (Andrew), Duignan, P., Duprex, W.P. (Paul), Early, G. (Greg), Fauquier, D. (Deborah), Goldstein, T. (Tracey), Goodman, S.J. (Simon J.), Grenfell, B.T. (Bryan), Groch, K.R. (Kátia R.), Gulland, F. (Frances), Hall, A. (Ailsa), Jensen, B.A. (Brenda A.), Lamy, K. (Karina), Matassa, K. (Keith), Mazzariol, S. (Sandro), Morris, S.E. (Sinead E.), Nielsen, O. (Ole), Rotstein, D. (David), Rowles, T.K. (Teresa K), Saliki, J. (Jeremy), Siebert, U. (Ursula), Swart, R.L. (Rik) de, Van Bressem, M.-F. (Marie-Françoise), Waltzek, T. (Thomas), Wellehan, J.F.X. (James F. X.)   +29 more
core   +1 more source

Molecular subtype concordance and metastatic patterns in muscle‐invasive bladder cancer

The Journal of Pathology: Clinical Research, Volume 12, Issue 3, May 2026.
Abstract Molecular subtypes are potential prognostic and predictive tools in muscle‐invasive bladder cancer (MIBC). However, subtype concordance between primary tumors and metastases, as well as subtype‐specific differences in metastatic patterns, remain poorly characterized.
Csilla Olah, Dániel Juhász, Melinda Váradi, Henning Reis, Mulham Al‐Nader, Osama Mahmoud, Barbara T. Grünwald, Viktor Grünwald, Boris Hadaschik, Péter Nyirády, Tibor Szarvas   +10 more
wiley   +1 more source

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin

Case Reports in Oncology, 2023
Enfortumab vedotin is an antibody-drug conjugate against nectin-4 that is recently being used in the management of patients with urothelial carcinoma. The common adverse events include rashes, peripheral neuropathy, and hyperglycemia. Only a few cases of
Takamasa Homma, Kuniaki Tanaka, Naoya Takeda, Yu Okada, Shota Torii, Hideki Esaki, Takashi Sakakibara, Norio Takimoto   +7 more
doaj   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

MedComm, Volume 7, Issue 4, April 2026.
Antibody–drug conjugates integrate antibody targeting with potent cytotoxic payloads to enable precision cancer therapy. Their clinical performance depends on coordinated optimization of engineering design, tumor antigen biology, and treatment strategy. Lessons from uro‐oncological malignancies illustrate how ADCs can be effectively developed, combined,
Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu   +6 more
wiley   +1 more source

Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease

The Journal of Pathology, Volume 268, Issue 4, Page 398-412, April 2026.
Abstract Crohn's disease (CD) involves chronic transmural inflammation of the intestines, leading to progressive wall fibrosis with stenosis and luminal obstruction, predominantly in the terminal ileum. Fibrosis is a significant therapeutic challenge, thus improved understanding of localisation, cellular composition, and cell–cell interactions in CD ...
Michael Glinka, Gregory J Wickham, Francesca Nadalin, Kathryn J Kirkwood, Helen Caldwell, Mike Wicks, Bill Hill, Derek Houghton, Mehran Sharghi, Amirhosein Kefayat, Bernard Haggarty, Albert Burger, Richard A Baldock, David J Adams, Irene Papatheodorou, Peter Bankhead, Shahida Din, Mark J Arends   +17 more
wiley   +1 more source

Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy [PDF]

, 2017
Adhesion to extracellular matrix (ECM) is crucially important for survival of normal epithelial cells as detachment from ECM triggers specific apoptosis known as anoikis.
A C Belkina, B E Pearson, M Lavaei, N Rahimi, N Woolf, P A Bondzie, R D Meyer, V Chitalia   +7 more
core   +1 more source

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 186-198, April 2026.
Skin adverse events (AEs) frequently accompany all types of anticancer treatments. This publication discusses how recent international guidance on best‐practices use of dermocosmetics can be adapted to the North Asia region (China, Hong Kong, Japan, Republic of Korea, and Taiwan).
Meng Pan, Jianguo Sun, Makoto Kawashima, You Chan Kim, Mison Chun, Chia‐Yu Chu, Yi‐Hsin Liang, Mee Chang, Delphine Kerob, Brigitte Dreno   +9 more
wiley   +1 more source